{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T22:00:49Z","timestamp":1780783249794,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Prim. Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>Type 2 diabetes (T2D) is a progressive disease often associated with comorbidities that complicate the management of T2D and affect the achievement of treatment targets. However, adherence to guidelines and individualized treatments can potentially improve treatment outcomes. This study assessed the association between different glucose lowering and lipid lowering medication lines and the achievement of treatment targets with different comorbidities among a T2D cohort in North Karelia, Finland (2011-12 to 2015-16).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The data on all diagnosed T2D patients (n\u2009=\u200910,190) in North Karelia were collated retrospectively from regional electronic health records (EHRs). Analyses were performed considering the age, sex, and comorbidities such as cardiovascular diseases (CVD) and any mental disorders (AMD). We analyzed the trends in using glucose lowering and lipid lowering medications and the effect of changes in medication on the achievement of treatment targets among different patient groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Metformin was the most common treatment in all patient groups. The use of only metformin declined and the use of metformin and\/or other non-insulin medications increased during the follow-up. A Combination of insulin and non-insulin medication was mostly used by T2D patients with both cardiovascular diseases and mental disorders (T2D\u2009+\u2009CVD\u2009+\u2009AMD), and the use of insulin increased among this group in follow-up. Achievement of the glucose treatment target deteriorated even after the intensification of medication among all patient groups during the follow-up. A considerably higher number of patients with T2D\u2009+\u2009AMD and T2D\u2009+\u2009CVD\u2009+\u2009AMD did not use lipid lowering medication when compared to the T2D\u2009+\u2009CVD patients both at baseline and follow-up. However, the achievement of the LDL treatment target improved during the follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Achievement of the glucose target deteriorated even after the intensification of treatment, and especially among patients with multiple diseases. Many T2D patients with AMD and CVD remained without lipid lowering medication, which needs further attention.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12875-022-01889-3","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T06:02:56Z","timestamp":1667973776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mode of treatments and achievement of treatment targets among type 2 diabetes patients with different comorbidities \u2013 a register-based retrospective cohort study in Finland"],"prefix":"10.1186","volume":"23","author":[{"given":"Nazma Akter","family":"Nazu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Leena","family":"Lamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaana","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilkka","family":"Tirkkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi","family":"Rautiainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Laatikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"1889_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 9th edn. International Diabetes Federation 2019, Brussels, Belgium."},{"key":"1889_CR2","unstructured":"Type 2 diabetes, Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim, the Finnish Society of Internal Medicine and the Finnish Diabetes Association. Helsinki, www.kaypahoito.fi; [ accessed 15th June, 2020]."},{"key":"1889_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol 2018; 17: 83\u2013018-0728-6.","journal-title":"Cardiovasc Diabetol"},{"key":"1889_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2337\/diacare.29.03.06.dc05-2078","volume":"29","author":"JD Piette","year":"2006","unstructured":"Piette JD, Kerr EA. The Impact of Comorbid Chronic Conditions on Diabetes Care. Diabetes Care. 2006;29:725\u201331.","journal-title":"Diabetes Care"},{"key":"1889_CR5","doi-asserted-by":"crossref","unstructured":"Goldberg RW, Kreyenbuhl JA, Medoff DR, Dickerson FB, Wohlheiter K, Fang LJ, et al. Quality of diabetes care among adults with serious mental illness. Psychiatric Services. 2007;58.","DOI":"10.1176\/ps.2007.58.4.536"},{"key":"1889_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jcjd.2013.01.026","volume":"37","author":"DJ Robinson","year":"2013","unstructured":"Robinson DJ, Luthra M, Vallis M. Diabetes and Mental Health. Can J Diabetes. 2013;37:87\u201392.","journal-title":"Can J Diabetes"},{"key":"1889_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jcjd.2017.10.031","volume":"42","author":"DJ Robinson","year":"2018","unstructured":"Robinson DJ, Coons M, Haensel H, Vallis M, Yale J. Diabetes and Mental Health. Can J Diabetes. 2018;42:130\u201341.","journal-title":"Can J Diabetes"},{"key":"1889_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12916-019-1373-y","volume":"17","author":"M Nowakowska","year":"2019","unstructured":"Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019;17:145.","journal-title":"BMC Med"},{"key":"1889_CR9","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes\u20142021. Diabetes Care 2021; 44: S73-S84.","DOI":"10.2337\/dc21-S006"},{"key":"1889_CR10","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669\u2013701.","journal-title":"Diabetes Care"},{"key":"1889_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","volume":"43","author":"JB Buse","year":"2019","unstructured":"Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2019;43:487\u201393.","journal-title":"Diabetes Care"},{"key":"1889_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2337\/dc08-S097","volume":"31","author":"MM Funnell","year":"2008","unstructured":"Funnell MM, Brown TL, Childs BP, Haas LB, Hosey GM, Jensen B, et al. National Standards for Diabetes Self-Management Education. Diabetes Care. 2008;31:97\u2013104.","journal-title":"Diabetes Care"},{"key":"1889_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1046\/j.1464-5491.2002.00718.x","volume":"19","author":"TM Wallace","year":"2002","unstructured":"Wallace TM, Matthews DR. Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes. Diabet Med. 2002;19:465\u20139.","journal-title":"Diabet Med"},{"key":"1889_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/dme.12459","volume":"31","author":"N Dubowitz","year":"2014","unstructured":"Dubowitz N, Xue W, Long Q, Ownby JG, Olson DE, Barb D, et al. Aging is associated with increased HbA1c levels, independently of glucose levels and insulin resistance, and also with decreased HbA1c diagnostic specificity. Diabet Med. 2014;31:927\u201335.","journal-title":"Diabet Med"},{"key":"1889_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/jdi.12175","volume":"5","author":"NS Ahmad","year":"2014","unstructured":"Ahmad NS, Farida I, Thomas P. Factors associated with good glycemic control among patients with type 2 diabetes mellitus. J Diabetes Invest. 2014;5:563\u20139.","journal-title":"J Diabetes Invest"},{"key":"1889_CR16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00125-017-4519-5","volume":"61","author":"LA Donnelly","year":"2018","unstructured":"Donnelly LA, Zhou K, Doney ASF, Jennison C, Franks PW, Pearson ER. Rates of glycaemic deterioration in a real-world population with type 2 diabetes. Diabetologia. 2018;61:607\u201315.","journal-title":"Diabetologia"},{"key":"1889_CR17","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.2337\/dc12-1759","volume":"36","author":"MA Stone","year":"2013","unstructured":"Stone MA, Charpentier G, Doggen K, Kuss O, Lindblad U, Kellner C, et al. Quality of care of people with type 2 diabetes in eight European countries: findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. Diabetes Care. 2013;36:2628\u201338.","journal-title":"Diabetes Care"},{"key":"1889_CR18","first-page":"2027","volume":"34","author":"H Tirkkonen","year":"2014","unstructured":"Tirkkonen H, Siki\u00f6 M, Kek\u00e4l\u00e4inen P, Laatikainen T. Tyypin 2 diabeteksen hoidossa merkitt\u00e4v\u00e4\u00e4 kuntakohtaista vaihtelua. (in Finnish). 2014;34:2027\u201332.","journal-title":"(in Finnish)"},{"key":"1889_CR19","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","volume":"281","author":"RC Turner","year":"1999","unstructured":"Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005\u201312.","journal-title":"JAMA"},{"key":"1889_CR20","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/j.1742-1241.2005.00675.x","volume":"59","author":"CJ Bailey","year":"2005","unstructured":"Bailey CJ, Del Prato S, Eddy D, Zinman B. Global Partnership for Effective Diabetes Management. Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control. Int J Clin Pract. 2005;59:1309\u201316.","journal-title":"Int J Clin Pract"},{"key":"1889_CR21","doi-asserted-by":"publisher","first-page":"e00019","DOI":"10.1002\/edm2.19","volume":"1","author":"EK Buysman","year":"2018","unstructured":"Buysman EK, Fan T, Blauer-Peterson C, Miller-Wilson LA. Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin. Endocrinol Diabetes Metab. 2018;1:e00019.","journal-title":"Endocrinol Diabetes Metab"},{"key":"1889_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.amjmed.2005.09.013","volume":"118","author":"J Betteridge","year":"2005","unstructured":"Betteridge J. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118:10\u20135.","journal-title":"Am J Med"},{"key":"1889_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","volume":"8","author":"N Wang","year":"2020","unstructured":"Wang N, Fulcher J, Abeysuriya N, Park L, Kumar S, Di Tanna GL, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. The Lancet Diabetes & Endocrinology. 2020;8:36\u201349.","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"1889_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"R Turner","year":"1998","unstructured":"United Kingdom prospective diabetes study group. Turner R. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837\u201353.","journal-title":"Lancet"},{"key":"1889_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13098-019-0476-0","volume":"11","author":"A Bashier","year":"2019","unstructured":"Bashier A, Bin Hussain A, Abdelgadir E, Alawadi F, Sabbour H, Chilton R. Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases. Diabetol Metab Syndr 2019; 11: 80\u2013019-0476-0.","journal-title":"Diabetol Metab Syndr"},{"key":"1889_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2337\/dc21-S009","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes\u20142021. Diabetes Care. 2021;44:111\u201324.","journal-title":"Diabetes Care"},{"key":"1889_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2337\/dc09-S301","volume":"32","author":"VA Fonseca","year":"2009","unstructured":"Fonseca VA. Defining and Characterizing the Progression of Type 2 Diabetes. Diabetes Care. 2009;32:151\u20136.","journal-title":"Diabetes Care"},{"key":"1889_CR28","unstructured":"Asefzadeh S, Asefzadeh M, Javadi H. Care management: adherence to therapies among patients at Bu-Alicina Clinic, Qazvin. Iran Pajouhesh Dar Pezeshki. 2005;10(6):343\u20138. 2005; 10: 343\u2013348."},{"key":"1889_CR29","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s11606-012-2136-z","volume":"27","author":"S Kripalani","year":"2012","unstructured":"Kripalani S, Schmotzer B, Jacobson TA. Improving Medication Adherence through Graphically Enhanced Interventions in Coronary Heart Disease (IMAGE-CHD): a randomized controlled trial. J Gen Intern Med. 2012;27:1609\u201317.","journal-title":"J Gen Intern Med"},{"key":"1889_CR30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140\u20139.","journal-title":"Diabetes Care"},{"key":"1889_CR31","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1001\/jama.2019.3805","volume":"321","author":"J Flory","year":"2019","unstructured":"Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321:1926\u20137.","journal-title":"JAMA"},{"key":"1889_CR32","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1210\/jc.2015-3754","volume":"101","author":"VR Aroda","year":"2016","unstructured":"Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101:1754\u201361.","journal-title":"J Clin Endocrinol Metab"},{"key":"1889_CR33","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","volume":"394","author":"DR Matthews","year":"2019","unstructured":"Matthews DR, Pald\u00e1nius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394:1519\u201329.","journal-title":"Lancet"},{"key":"1889_CR34","doi-asserted-by":"publisher","first-page":"740","DOI":"10.7326\/M15-2650","volume":"164","author":"NM Maruthur","year":"2016","unstructured":"Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;164:740\u201351.","journal-title":"Ann Intern Med"},{"key":"1889_CR35","first-page":"850","volume":"42","author":"MF Harris","year":"2013","unstructured":"Harris MF, Dennis S, Pillay M. Multimorbidity: negotiating priorities and making progress. Aust Fam Physician. 2013;42:850\u20134.","journal-title":"Aust Fam Physician"},{"key":"1889_CR36","doi-asserted-by":"crossref","unstructured":"Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. The Lancet 2010; 376.","DOI":"10.1016\/S0140-6736(10)60576-4"},{"key":"1889_CR37","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"The ADVANCE Collaborative Group","year":"2008","unstructured":"The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008;358:2560\u201372.","journal-title":"N Engl J Med"},{"key":"1889_CR38","doi-asserted-by":"publisher","first-page":"856","DOI":"10.4088\/JCP.v63n1002","volume":"63","author":"DA Wirshing","year":"2002","unstructured":"Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63:856\u201365.","journal-title":"J Clin Psychiatry"},{"key":"1889_CR39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12888-017-1539-0","volume":"17","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry 2017; 17: 373\u2013017-1539-0.","journal-title":"BMC Psychiatry"},{"key":"1889_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12933-016-0400-y","volume":"15","author":"MB Mortensen","year":"2016","unstructured":"Mortensen MB, Kulenovic I, Falk E. Statin use and cardiovascular risk factors in diabetic patients developing a first myocardial infarction. Cardiovasc Diabetol. 2016;15:81.","journal-title":"Cardiovasc Diabetol"},{"key":"1889_CR41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12933-018-0738-4","volume":"17","author":"MF van Stee","year":"2018","unstructured":"van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovasc Diabetol 2018; 17: 94\u2013018-0738-4.","journal-title":"Cardiovasc Diabetol"},{"key":"1889_CR42","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1192\/j.eurpsy.2020.94","volume":"63","author":"V Salvi","year":"2020","unstructured":"Salvi V, Aguglia A, Barone-Adesi F, Bianchi D, Donfrancesco C, Dragogna F, et al. Cardiovascular risk in patients with severe mental illness in Italy. Eur Psychiatry. 2020;63:e96.","journal-title":"Eur Psychiatry"},{"key":"1889_CR43","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41569-020-00463-7","volume":"18","author":"RE Nielsen","year":"2021","unstructured":"Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness. Nat Rev Cardiol. 2021;18:136\u201345.","journal-title":"Nat Rev Cardiol"},{"key":"1889_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12913-020-06030-7","volume":"21","author":"CM Collopy","year":"2021","unstructured":"Collopy CM, Cosh SM, Tully PJ. Screening and referral is not enough: a qualitative exploration of barriers to access and uptake of mental health services in patients with cardiovascular diseases. BMC Health Serv Res. 2021;21:49.","journal-title":"BMC Health Serv Res"},{"key":"1889_CR45","doi-asserted-by":"crossref","unstructured":"Gant CM, Binnenmars SH, Harmelink M, Soedamah-Muthu SS, Bakker SJL, Navis G, et al. Real-life achievement of lipid-lowering treatment targets in the Diabetes and Lifestyle Cohort Twente: systemic assessment of pharmacological and nutritional factors. Nutr Diabetes 2018; 8: 24-018-0028-y.","DOI":"10.1038\/s41387-018-0028-y"}],"container-title":["BMC Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-022-01889-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12875-022-01889-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-022-01889-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T06:03:05Z","timestamp":1667973785000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcfampract.biomedcentral.com\/articles\/10.1186\/s12875-022-01889-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1889"],"URL":"https:\/\/doi.org\/10.1186\/s12875-022-01889-3","relation":{},"ISSN":["2731-4553"],"issn-type":[{"value":"2731-4553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"22 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the use of the electronic patient record data of the Hospital District of North Karelia is received from the ethics committee of the Northern Savo Hospital District on 13th November 2012. The need for informed consent was waived by the \u201cEthics Committee of the Northern Savo Hospital District\u201d, because of the retrospective nature of the study. The Finnish legislation do not require informed consent for register-based research when study is solely based on registers (involving no contact with the study subjects) and the study is considered to be of public health importance. All methods were carried out in accordance with the relevant guidelines and regulations or declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"278"}}